Advertisement
Advertisement
NVCR
NovoCure Limited Ordinary Shares
17.90
USDSponsored
+0.15
+0.85%
May 21, 16:00 UTC -4
Closed
After-Market
17.99
+0.09
+0.50%
NVCR Earnings Reports
Positive Surprise Ratio
NVCR beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Jul 20, 2026
Estimate for Q2 26 (Revenue/ EPS)
$176.17M
/-$0.33
Implied change from Q1 26 (Revenue/ EPS)
+1.22%
/-46.77%
Implied change from Q2 25 (Revenue/ EPS)
+10.94%
/-8.33%
NovoCure Limited Ordinary Shares earnings per share and revenue
On Apr 30, 2026, NVCR reported earnings of -0.62 USD per share (EPS) for Q1 26, missing the estimate of -0.52 USD, resulting in a -18.52% surprise. Revenue reached 174.06 million, compared to an expected 171.22 million, with a 1.65% difference. The market reacted with a +27.49% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.33 USD, with revenue projected to reach 176.17 million USD, implying an decrease of -46.77% EPS, and increase of 1.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, NovoCure Limited Ordinary Shares reported EPS of -$0.62, missing estimates by -18.52%, and revenue of $174.06M, 1.65% above expectations.
How did the market react to NovoCure Limited Ordinary Shares's Q1 2026 earnings?
The stock price moved up 27.49%, changed from $11.93 before the earnings release to $15.21 the day after.
When is NovoCure Limited Ordinary Shares expected to report next?
The next earning report is scheduled for Jul 20, 2026.
What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?
Based on --
analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.33 and revenue of $176.17M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement